Pancreatic Cancer Therapeutics & Diagnostics Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Pancreatic Cancer Therapeutics & Diagnostics Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type (Treatment {Targeted Therapies, Chemotherapy, Surgery, Other}, Diagnostics {Imaging, Biopsy, Endoscopic Ultrasound, Other}), By End-User (Hospital & Clinic, Ambulatory Centers, Others) By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Pancreatic Cancer Therapeutics & Diagnostics Market is projected to grow from USD 4.72 Billion in 2025 to USD 7.31 Billion by 2031, at a 7.56% CAGR. This market includes pharmaceutical treatments like chemotherapies and targeted immunotherapies, alongside advanced imaging and molecular biomarker assays for disease identification and staging. Growth is structurally driven by an expanding geriatric population and the rising global prevalence of lifestyle-related risk factors such as type 2 diabetes and obesity, necessitating increased oncological interventions. However, a significant obstacle is the persistent late-stage diagnosis, which severely limits treatment efficacy and curative surgical options for most patients. The asymptomatic nature of early-stage disease leads to poor prognoses and a restricted patient pool for new therapies, underlined by a critically low 13% five-year relative survival rate in 2025, according to the American Cancer Society, highlighting substantial clinical gaps.
Market Driver
The primary structural catalyst for market expansion is the increasing global incidence and prevalence of pancreatic cancer, demanding urgent advancements in clinical management. As populations age and lifestyle risk factors like obesity and diabetes become more widespread, the number of patients requiring oncological intervention has steadily grown, driving demand for diagnostic screenings and therapeutic regimens. For example, the American Cancer Society reported an estimated 67,440 new cases in the United States alone in January 2025, emphasizing the critical need for scalable medical solutions. Simultaneously, the market is being transformed by novel immunotherapies and targeted therapeutic agents, shifting treatment paradigms from conventional chemotherapies towards precision oncology. Pharmaceutical pipelines increasingly leverage specific biomarkers for improved patient outcomes, with a notable breakthrough being the 83% overall response rate achieved by avutometinib and defactinib in metastatic pancreatic ductal adenocarcinoma patients, as highlighted by Verastem Oncology in May 2025. These therapeutic strides are complemented by innovations in detection, such as the FDA's breakthrough device designation for DAMO PANDA, an AI-powered model for pancreatic cancer detection, signaling a parallel commitment to enhancing early-stage diagnosis and survival prospects.
Market Challenge
A significant restriction on the commercial scalability of the Global Pancreatic Cancer Therapeutics & Diagnostics Market is the persistent challenge of late-stage diagnosis. Since the disease typically progresses without specific symptoms until metastasis, most patients are ineligible for curative surgical interventions upon identification. This delay shifts the primary clinical focus from long-term disease management to short-term palliative care, drastically compressing the therapeutic window. Consequently, sustained administration of pharmaceutical agents is hindered, reducing the total drug volume dispensed per patient compared to other chronic oncology indications. This rapid clinical decline severely limits the addressable patient pool needed for high-volume market growth. The high attrition rate means eligible patient populations for novel therapies turn over quickly, preventing developers from accumulating a stable revenue base. This trend is underscored by the narrow gap between incidence and mortality, with an estimated 51,980 pancreatic cancer deaths in the United States in 2025, according to the American Cancer Society, which directly dampens overall market valuation by making it difficult to maintain viable patient cohorts for extended regimens.
Market Trends
The emergence of KRAS-targeted therapeutic agents represents a pivotal shift in treating pancreatic ductal adenocarcinoma, specifically addressing mutations previously considered undruggable. While earlier efforts focused on rare G12C mutations, recent clinical progress has successfully targeted the more prevalent G12D variant, offering new hope for refractory cases. This trend moves beyond broad-spectrum chemotherapy to directly silence the oncogenic driver, establishing a precise mechanism of action for a larger patient subset. A notable advancement was reported by VJOncology in October 2025, where investigational KRAS G12D inhibitors demonstrated overall response rates of 30% to 50% in pre-treated patients, signifying a major leap in precision oncology and potentially a new standard of care. Simultaneously, the proliferation of liquid biopsy and blood-based biomarkers is fundamentally altering the diagnostic landscape by enabling non-invasive, early-stage detection. This trend addresses the critical need for screening tools that can identify malignancy before metastasis, significantly expanding the curative window. Developers are leveraging multi-analyte assays combining mRNA signatures with advanced algorithms for unprecedented accuracy, as exemplified by Mainz Biomed's proprietary PancAlert test achieving 100% sensitivity and 95% specificity in distinguishing pancreatic cancer patients from healthy controls in October 2025. Such high-fidelity diagnostics are essential for shifting market value from palliative management to curative interventions, driving long-term growth through increased surgical eligibility and survivorship.
Key Market Players
* Myriad Genetics Inc.
* Pfizer Inc.
* Novartis AG
* Bristol-Myers Squibb Company
* AstraZeneca PLC
* Amgen Inc.
* Viatris Inc.
* Boston Scientific Corporation
* FUJIFILM Holdings Corporation
* Canon Inc.
* Rafael Holdings Inc
Report Scope
In this report, the Global Pancreatic Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Pancreatic Cancer Therapeutics & Diagnostics Market, By Type
* Treatment
* Diagnostics
# Pancreatic Cancer Therapeutics & Diagnostics Market, By End-User
* Hospital & Clinic
* Ambulatory Centers
* Others
# Pancreatic Cancer Therapeutics & Diagnostics Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Therapeutics & Diagnostics Market.
Available Customizations:
Global Pancreatic Cancer Therapeutics & Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Treatment {Targeted Therapies, Chemotherapy, Surgery, Other}, Diagnostics {Imaging, Biopsy, Endoscopic Ultrasound, Other})
5.2.2. By End-User (Hospital & Clinic, Ambulatory Centers, Others)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. North America Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By End-User
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By End-User
6.3.2. Canada Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By End-User
6.3.3. Mexico Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By End-User
7. Europe Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By End-User
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By End-User
7.3.2. France Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By End-User
7.3.3. United Kingdom Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By End-User
7.3.4. Italy Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By End-User
7.3.5. Spain Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By End-User
8. Asia Pacific Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By End-User
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By End-User
8.3.2. India Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By End-User
8.3.3. Japan Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By End-User
8.3.4. South Korea Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By End-User
8.3.5. Australia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By End-User
9. Middle East & Africa Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By End-User
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By End-User
9.3.2. UAE Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By End-User
9.3.3. South Africa Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By End-User
10. South America Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By End-User
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By End-User
10.3.2. Colombia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By End-User
10.3.3. Argentina Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By End-User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Pancreatic Cancer Therapeutics & Diagnostics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Myriad Genetics Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Pfizer Inc.
15.3. Novartis AG
15.4. Bristol-Myers Squibb Company
15.5. AstraZeneca PLC
15.6. Amgen Inc.
15.7. Viatris Inc.
15.8. Boston Scientific Corporation
15.9. FUJIFILM Holdings Corporation
15.10. Canon Inc.
15.11. Rafael Holdings Inc
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們